169 related articles for article (PubMed ID: 17361207)
21. Cytologic malignancy versus benignancy: how useful are the "newer" markers in body fluid cytology?
Lyons-Boudreaux V; Mody DR; Zhai J; Coffey D
Arch Pathol Lab Med; 2008 Jan; 132(1):23-8. PubMed ID: 18181669
[TBL] [Abstract][Full Text] [Related]
22. Usefulness of p16/CDKN2A fluorescence in situ hybridization and BAP1 immunohistochemistry for the diagnosis of biphasic mesothelioma.
Wu D; Hiroshima K; Yusa T; Ozaki D; Koh E; Sekine Y; Matsumoto S; Nabeshima K; Sato A; Tsujimura T; Yamakawa H; Tada Y; Shimada H; Tagawa M
Ann Diagn Pathol; 2017 Feb; 26():31-37. PubMed ID: 28038708
[TBL] [Abstract][Full Text] [Related]
23. Spindle cell tumours of the pleura: a clinical, histological and comparative genomic hybridization analysis of 14 cases.
Knuuttila A; Jee KJ; Taskinen E; Wolff H; Knuutila S; Anttila S
Virchows Arch; 2006 Feb; 448(2):135-41. PubMed ID: 16170537
[TBL] [Abstract][Full Text] [Related]
24. Sarcomatoid mesothelioma: a clinical-pathologic correlation of 326 cases.
Klebe S; Brownlee NA; Mahar A; Burchette JL; Sporn TA; Vollmer RT; Roggli VL
Mod Pathol; 2010 Mar; 23(3):470-9. PubMed ID: 20081811
[TBL] [Abstract][Full Text] [Related]
25. Malignant mesothelioma with heterologous elements: clinicopathological correlation of 27 cases and literature review.
Klebe S; Mahar A; Henderson DW; Roggli VL
Mod Pathol; 2008 Sep; 21(9):1084-94. PubMed ID: 18587319
[TBL] [Abstract][Full Text] [Related]
26. p16 Deletion in sarcomatoid tumors of the lung and pleura.
Tochigi N; Attanoos R; Chirieac LR; Allen TC; Cagle PT; Dacic S
Arch Pathol Lab Med; 2013 May; 137(5):632-6. PubMed ID: 23627453
[TBL] [Abstract][Full Text] [Related]
27. Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma.
Mimura T; Ito A; Sakuma T; Ohbayashi C; Yoshimura M; Tsubota N; Okita Y; Okada M
Cancer; 2007 Mar; 109(5):933-8. PubMed ID: 17279584
[TBL] [Abstract][Full Text] [Related]
28. Characterizing the distribution of alterations in mesothelioma and their correlation to morphology.
Chen-Yost HI; Tjota MY; Gao G; Mitchell O; Kindler H; Segal J; Husain AN; Mueller J; Schulte JJ
Am J Clin Pathol; 2023 Sep; 160(3):238-246. PubMed ID: 37141416
[TBL] [Abstract][Full Text] [Related]
29. D2-40: a reliable marker in the diagnosis of pleural mesothelioma.
Müller AM; Franke FE; Müller KM
Pathobiology; 2006; 73(1):50-4. PubMed ID: 16785767
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic usefulness of p16/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis.
Wu D; Hiroshima K; Matsumoto S; Nabeshima K; Yusa T; Ozaki D; Fujino M; Yamakawa H; Nakatani Y; Tada Y; Shimada H; Tagawa M
Am J Clin Pathol; 2013 Jan; 139(1):39-46. PubMed ID: 23270897
[TBL] [Abstract][Full Text] [Related]
31. Frequent expression of conventional endothelial markers in pleural mesothelioma: usefulness of claudin-5 as well as combined traditional markers to distinguish mesothelioma from angiosarcoma.
Nakashima Y; Inamura K; Ninomiya H; Okumura S; Mun M; Kirimura S; Kobayashi M; Okubo K; Ishikawa Y
Lung Cancer; 2020 Oct; 148():20-27. PubMed ID: 32777673
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic utility of immunohistochemistry in distinguishing between epithelioid pleural mesotheliomas and breast carcinomas: a comparative study.
Ordóñez NG; Sahin AA
Hum Pathol; 2014 Jul; 45(7):1529-40. PubMed ID: 24816068
[TBL] [Abstract][Full Text] [Related]
33. Expression of carbonic anhydrase IX (CAIX) in malignant mesothelioma. An immunohistochemical and immunocytochemical study.
Capkova L; Koubkova L; Kodet R
Neoplasma; 2014; 61(2):161-9. PubMed ID: 24471939
[TBL] [Abstract][Full Text] [Related]
34. Calretinin: a novel immunocytochemical marker for mesothelioma.
Doglioni C; Dei Tos AP; Laurino L; Iuzzolino P; Chiarelli C; Celio MR; Viale G
Am J Surg Pathol; 1996 Sep; 20(9):1037-46. PubMed ID: 8764740
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical differentiation of sarcomatoid mesotheliomas from other spindle cell neoplasms.
Cagle PT; Truong LD; Roggli VL; Greenberg SD
Am J Clin Pathol; 1989 Nov; 92(5):566-71. PubMed ID: 2479255
[TBL] [Abstract][Full Text] [Related]
36. V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma.
Muller S; Victoria Lai W; Adusumilli PS; Desmeules P; Frosina D; Jungbluth A; Ni A; Eguchi T; Travis WD; Ladanyi M; Zauderer MG; Sauter JL
Mod Pathol; 2020 Feb; 33(2):303-311. PubMed ID: 31537897
[TBL] [Abstract][Full Text] [Related]
37. Expression of mesothelial markers in malignant mesotheliomas: an immunohistochemical evaluation of 173 cases.
Soomro IN; Oliveira R; Ronan J; Chaudry ZR; Johnson J
J Pak Med Assoc; 2005 May; 55(5):205-9. PubMed ID: 15960287
[TBL] [Abstract][Full Text] [Related]
38. Calretinin but not caveolin-1 correlates with tumour histology and survival in malignant mesothelioma.
Thapa B; Walkiewicz M; Murone C; Asadi K; Deb S; Barnett S; Knight S; Mitchell P; Liew D; Watkins DN; John T
Pathology; 2016 Dec; 48(7):660-665. PubMed ID: 27780599
[TBL] [Abstract][Full Text] [Related]
39. The diagnostic utility of D2-40, calretinin, CK5/6, desmin and MOC-31 in the differentiation of mesothelioma from adenocarcinoma in pleural effusion cytology.
Hyun TS; Barnes M; Tabatabai ZL
Acta Cytol; 2012; 56(5):527-32. PubMed ID: 23075894
[TBL] [Abstract][Full Text] [Related]
40. Immunohistochemical diagnosis of epithelioid mesothelioma: an update.
Ordóñez NG
Arch Pathol Lab Med; 2005 Nov; 129(11):1407-14. PubMed ID: 16253021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]